Debevoise & Plimpton LLP
Fried, Frank, Harris, Shriver & Jacobson LLP
Mark is an accomplished and versatile corporate and transactional attorney in the life sciences industry with over 25 years of experience. Mark has extensive experience advising, structuring, drafting and negotiating strategic transactions (research, development and commercialization) at all stages of the product lifecycle, most recently in-house at Pfizer.
Mark’s deal experience in life sciences includes advising on and negotiating research collaborations, exclusive in-licenses and out-licenses, company and asset acquisitions and divestitures, spin-outs, strategic and venture equity and debt investments, FTO licenses, development funding collaborations, sponsored research agreements, device, diagnostic and biomarker agreements, confidentiality agreements and material transfer agreements. Having advised C-suite executives and senior leadership teams for Pfizer’s R&D organization for over a decade, he has a firm working knowledge of the science behind emerging technologies and product modalities, including RNAi and gene therapy. Mark has also been involved in the formation of new entities and corporate restructuring projects. Mark started his career as a lawyer at a top tier international law firm in New York focusing on M&A, securities law and structured finance.
Mark frequently presents on transactional issues within the life sciences sector. Mark’s recent engagements include:
Mark frequently takes on pro bono work. Recent engagements include projects for Lawyer’s Alliance for New York and for Brooklyn Bar Association Volunteer Lawyers Project.